Silvia C Sookoian

List of Publications by Year in Descending Order

137 papers	8,043 citations	47 h-index	88 g-index
152 ext. papers	10,073 ext. citations	6.7 avg, IF	6.61 L-index

#	Paper	IF	Citations
137	The influence of host genetics on liver microbiome composition in patients with NAFLD.. *EBioMedicine*, **2022**, 76, 103858	8.8	3
136	Computational Pipeline for Next-Generation Sequencing (NGS) Studies in Genetics of NASH.. *Methods in Molecular Biology*, **2022**, 2455, 203-222	1.4	0
135	MicroRNAs as messengers of liver diseases: has the message finally been decrypted?. *Clinical Science*, **2022**, 136, 323-328	6.5	1
134	Liver tissue microbiota in nonalcoholic liver disease: a change in the paradigm of host-bacterial interactions. *Hepatobiliary Surgery and Nutrition*, **2021**, 10, 337-349	2.1	1
133	Liver mitochondrial DNA damage and genetic variability of Cytochrome b - a key component of the respirasome - drive the severity of fatty liver disease. *Journal of Internal Medicine*, **2021**, 289, 84-96	10.8	12
132	The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD. *Clinical and Translational Gastroenterology*, **2021**, 12, e00400	4.2	1
131	Genome-wide Association Study of Liver-related Enzymes Suggests Putative Pleiotropic Effects on Diverse Traits and Diseases. *Hepatology*, **2021**, 74, 3529-3533	11.2	0
130	PNPLA3 and COVID-19 outcomes: Thinking outside the box might explain the biology behind pleiotropic effects of rs738409 on the immune system. *Liver International*, **2021**, 41, 2801-2804	7.9	2
129	The lipidome in nonalcoholic fatty liver disease: actionable targets. *Journal of Lipid Research*, **2021**, 62, 100073	6.3	3
128	Pleiotropy within gene variants associated with nonalcoholic fatty liver disease and traits of the hematopoietic system. *World Journal of Gastroenterology*, **2021**, 27, 305-320	5.6	1
127	Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis. *Journal of Infection*, **2020**, 81, 276-281	18.9	55
126	Epigenetics factors in nonalcoholic fatty liver disease. *Expert Review of Gastroenterology and Hepatology*, **2020**, 1-16	4.2	4
125	Age but not sex may explain the negative effect of arterial hypertension and diabetes on COVID-19 prognosis. *Journal of Infection*, **2020**, 81, 647-679	18.9	3
124	Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology. *Hepatology*, **2020**, 72, 330-346	11.2	36
123	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. *Gastroenterology*, **2020**, 158, 1999-2014.e1	13.3	748
122	COVID-19 and ACE2 in the Liver and Gastrointestinal Tract: Putative Biological Explanations of Sexual Dimorphism. *Gastroenterology*, **2020**, 159, 1620-1621	13.3	16
121	SARS-CoV-2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID-19. *Liver International*, **2020**, 40, 2038-2040	7.9	47

120	Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology. *Clinical and Molecular Hepatology*, **2020**, 26, 461-475	6.9	13
119	ADH1B*2 Is Associated With Reduced Severity of Nonalcoholic Fatty Liver Disease in Adults, Independent of Alcohol Consumption. *Gastroenterology*, **2020**, 159, 929-943	13.3	4
118	Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. *Gut*, **2020**, 69, 1483-1491	19.2	56
117	Review article: shared disease mechanisms between non-alcoholic fatty liver disease and metabolic syndrome - translating knowledge from systems biology to the bedside. *Alimentary Pharmacology and Therapeutics*, **2019**, 49, 516-527	6.1	20
116	Repurposing drugs to target nonalcoholic steatohepatitis. *World Journal of Gastroenterology*, **2019**, 25, 1783-1796	5.6	11
115	Genetics of Nonalcoholic Fatty Liver Disease: From Pathogenesis to Therapeutics. *Seminars in Liver Disease*, **2019**, 39, 124-140	7.3	32
114	Genetics Meets Therapy? Exome-wide Association Study Reveals a Loss-of-Function Variant in 17-Beta-Hydroxysteroid Dehydrogenase 13 That Protects Patients From Liver Damage and Nonalcoholic Fatty Liver Disease Progression. *Hepatology*, **2019**, 69, 907-910	11.2	7
113	Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease. *Journal of Lipid Research*, **2019**, 60, 176-185	6.3	75
112	Metastasis-associated lung adenocarcinoma transcript 1 as a common molecular driver in the pathogenesis of nonalcoholic steatohepatitis and chronic immune-mediated liver damage. *Hepatology Communications*, **2018**, 2, 654-665	6	20
111	Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 16-25	6.1	45
110	Lack of evidence supporting a role of TMC4-rs641738 missense variant-MBOAT7- intergenic downstream variant-in the Susceptibility to Nonalcoholic Fatty Liver Disease. *Scientific Reports*, **2018**, 8, 5097	4.9	29
109	The nonalcoholic steatohepatitis metabotype: Imbalance of circulating amino acids and transamination reactions reflect impaired mitochondrial function. *Hepatology*, **2018**, 67, 1177-1178	11.2	6
108	Nonalcoholic Fatty Liver Disease Progresses into Severe NASH when Physiological Mechanisms of Tissue Homeostasis Collapse. *Annals of Hepatology*, **2018**, 17, 182-186	3.1	2
107	Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity. *World Journal of Gastroenterology*, **2018**, 24, 1601-1615	5.6	39
106	A Rare Nonsense Mutation in the Glucokinase Regulator Gene Is Associated With a Rapidly Progressive Clinical Form of Nonalcoholic Steatohepatitis. *Hepatology Communications*, **2018**, 2, 1030-1036	6	6
105	Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. *Nature Reviews Gastroenterology and Hepatology*, **2018**, 15, 461-478	24.2	206
104	Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. *Alimentary Pharmacology and Therapeutics*, **2017**, 46, 85-95	6.1	94
103	Genetic predisposition in nonalcoholic fatty liver disease. *Clinical and Molecular Hepatology*, **2017**, 23, 1-12	6.9	112

102	Letter: Mendelian randomisation to investigate moderate alcohol consumption in nonalcoholic fatty liver disease; modest effects need large numbers-authorsSreply. *Alimentary Pharmacology and Therapeutics*, **2017**, 46, 469-470	6.1	
101	Serotonin-transporter promoter polymorphism modulates the ability to control food intake: Effect on total weight loss. *Molecular Nutrition and Food Research*, **2017**, 61, 1700494	5.9	3
100	Nonalcoholic fatty liver disease: Biomarkers support decisions around pharmacological intervention. *Hepatology*, **2017**, 65, 1417-1419	11.2	1
99	Nonalcoholic steatohepatitis is associated with a state of betaine-insufficiency. *Liver International*, **2017**, 37, 611-619	7.9	34
98	Genetic variation in long noncoding RNAs and the risk of nonalcoholic fatty liver disease. *Oncotarget*, **2017**, 8, 22917-22926	3.3	25
97	Non-alcoholic fatty liver disease and risk of cardiovascular disease. *Metabolism: Clinical and Experimental*, **2016**, 65, 1136-50	12.7	152
96	Mitochondrial genome architecture in non-alcoholic fatty liver disease. *Journal of Pathology*, **2016**, 240, 437-449	9.4	38
95	Meta-analysis of the influence of TM6SF2 E167K variant on Plasma Concentration of Aminotransferases across different Populations and Diverse Liver Phenotypes. *Scientific Reports*, **2016**, 6, 27718	4.9	16
94	The modulation of liver methylome in liver diseases. *Journal of Hepatology*, **2016**, 64, 987-8	13.4	2
93	Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level. *American Journal of Clinical Nutrition*, **2016**, 103, 422-34	7	61
92	How Safe Is Moderate Alcohol Consumption in Overweight and Obese Individuals?. *Gastroenterology*, **2016**, 150, 1698-1703.e2	13.3	26
91	Metabolite Signatures of Metabolic Risk Factors and their Longitudinal Changes. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 1779-89	5.6	14
90	Genetic Basis of Alcoholic and Nonalcoholic Fatty Liver Disease **2016**, 147-163		
89	Heat Shock Protein 27 is down-regulated in Ballooned Hepatocytes of Patients with Nonalcoholic Steatohepatitis (NASH). *Scientific Reports*, **2016**, 6, 22528	4.9	10
88	Mendelian randomisation suggests no beneficial effect of moderate alcohol consumption on the severity of nonalcoholic fatty liver disease. *Alimentary Pharmacology and Therapeutics*, **2016**, 44, 1224-1234	6.1	22
87	The Exact Mechanism by Which Hepatic Transmembrane 6 Superfamily Member 2 Modulates Triglyceride Metabolism Is Still Uncertain. *Gastroenterology*, **2016**, 151, 1033-1034	13.3	1
86	Elafibranor for the treatment of NAFLD: One pill, two molecular targets and multiple effects in a complex phenotype. *Annals of Hepatology*, **2016**, 15, 604-9	3.1	10
85	PNPLA3 I148M variant is associated with metabolic stress-response phenotype in patients with nonalcoholic fatty liver disease. *Hepatology*, **2015**, 61, 1769	11.2	5

84	Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. *Gut*, **2015**, 64, 800-12	19.2	336
83	Nonalcoholic fatty liver disease. *Nature Reviews Disease Primers*, **2015**, 1, 15080	51.1	366
82	Epigenetic Modifications in the Biology of Nonalcoholic Fatty Liver Disease: The Role of DNA Hydroxymethylation and TET Proteins. *Medicine (United States)*, **2015**, 94, e1480	1.8	49
81	The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis. *Hepatology*, **2015**, 62, 1742-56	11.2	104
80	Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. *Hepatology*, **2015**, 61, 515-25	11.2	136
79	Telomere length in the two extremes of abnormal fetal growth and the programming effect of maternal arterial hypertension. *Scientific Reports*, **2015**, 5, 7869	4.9	22
78	Glutamine-Cycling Pathway in Metabolic Syndrome: Systems Biology-Based Characterization of the Glutamate-Related Metabolotype and Advances for Diagnosis and Treatment in Translational Medicine **2015**, 255-275		0
77	Genetic and Epigenetic Associations with NAFLD: Focus on Clinical Decision Making and Novel Concepts in Disease Pathogenesis. *Current Hepatology Reports*, **2014**, 13, 97-105	1	
76	Metabolic profiling reveals that PNPLA3 induces widespread effects on metabolism beyond triacylglycerol remodeling in Huh-7 hepatoma cells. *American Journal of Physiology - Renal Physiology*, **2014**, 307, G66-76	5.1	35
75	Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals. *Gut*, **2014**, 63, 530-2	19.2	80
74	Personalizing care for nonalcoholic fatty liver disease patients: what are the research priorities?. *Personalized Medicine*, **2014**, 11, 735-743	2.2	5
73	Promoter DNA methylation of farnesoid X receptor and pregnane X receptor modulates the intrahepatic cholestasis of pregnancy phenotype. *PLoS ONE*, **2014**, 9, e87697	3.7	12
72	Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: a meta-analysis. *Obesity Surgery*, **2013**, 23, 1815-25	3.7	64
71	Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. *Gut*, **2013**, 62, 1356-63	19.2	235
70	Fetal metabolic programming and epigenetic modifications: a systems biology approach. *Pediatric Research*, **2013**, 73, 531-42	3.2	75
69	Epigenetics of insulin resistance: an emerging field in translational medicine. *Current Diabetes Reports*, **2013**, 13, 229-37	5.6	12
68	Circulating MicroRNA-122 signature in nonalcoholic fatty liver disease and cardiovascular disease: a new endocrine system in metabolic syndrome. *Hepatology*, **2013**, 57, 2545-7	11.2	21
67	Maternal high-fat intake during pregnancy programs metabolic-syndrome-related phenotypes through liver mitochondrial DNA copy number and transcriptional activity of liver PPARGC1A. *Journal of Nutritional Biochemistry*, **2013**, 24, 6-13	6.3	82

66	Cardiovascular disease is associated with high-fat-diet-induced liver damage and up-regulation of the hepatic expression of hypoxia-inducible factor 1 in a rat model. *Clinical Science*, **2013**, 124, 53-63	6.5	23
65	Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease. *PLoS ONE*, **2013**, 8, e58895	3.7	37
64	Fatty liver is associated with transcriptional downregulation of stearoyl-CoA desaturase and impaired protein dimerization. *PLoS ONE*, **2013**, 8, e76912	3.7	17
63	Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD. *Current Pharmaceutical Design*, **2013**, 19, 5177-5192	3.3	80
62	Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD. *Current Pharmaceutical Design*, **2013**, 19, 5177-5192	3.3	70
61	Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. *Current Pharmaceutical Design*, **2013**, 19, 5177-92	3.3	45
60	Effects of bile acid sequestration on hepatic steatosis in obese mice. *Annals of Hepatology*, **2013**, 13, 105-12	3.1	3
59	The genetic epidemiology of nonalcoholic fatty liver disease: toward a personalized medicine. *Clinics in Liver Disease*, **2012**, 16, 467-85	4.6	36
58	Genetic determinants of acquired cholestasis: a systems biology approach. *Frontiers in Bioscience - Landmark*, **2012**, 17, 206-20	2.8	3
57	Alanine and aspartate aminotransferase and glutamine-cycling pathway: their roles in pathogenesis of metabolic syndrome. *World Journal of Gastroenterology*, **2012**, 18, 3775-81	5.6	111
56	DNA methylation and hepatic insulin resistance and steatosis. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2012**, 15, 350-6	3.8	24
55	PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma, and nonalcoholic fatty liver disease. *World Journal of Gastroenterology*, **2012**, 18, 6018-26	5.6	40
54	Odor perception between heterosexual partners: its association with depression, anxiety, and genetic variation in odorant receptor OR7D4. *Biological Psychology*, **2011**, 86, 153-7	3.2	13
53	Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. *Atherosclerosis*, **2011**, 218, 378-85	3.1	73
52	High fat diet-induced liver steatosis promotes an increase in liver mitochondrial biogenesis in response to hypoxia. *Journal of Cellular and Molecular Medicine*, **2011**, 15, 1329-38	5.6	74
51	Metabolic syndrome: from the genetics to the pathophysiology. *Current Hypertension Reports*, **2011** , 13, 149-57	4.7	65
50	Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. *Hepatology*, **2011**, 53, 1883-94	11.2	608
49	Cyclooxygenase inhibition up-regulates liver carnitine palmitoyltransferase 1A expression and improves fatty liver. *Hepatology*, **2011**, 53, 2143-4; author reply 2145-6	11.2	4

48	Reply:. *Hepatology*, **2011**, 53, 2146-2147	11.2	
47	The influence of common gene variants of the xenobiotic receptor (PXR) in genetic susceptibility to intrahepatic cholestasis of pregnancy. *Alimentary Pharmacology and Therapeutics*, **2010**, 31, 583-92	6.1	32
46	Gene-gene interaction between serotonin transporter (SLC6A4) and CLOCK modulates the risk of metabolic syndrome in rotating shiftworkers. *Chronobiology International*, **2010**, 27, 1202-18	3.6	22
45	Influence of hepatocyte nuclear factor 4alpha (HNF4alpha) gene variants on the risk of type 2 diabetes: a meta-analysis in 49,577 individuals. *Molecular Genetics and Metabolism*, **2010**, 99, 80-9	3.7	20
44	Methylation of TFAM gene promoter in peripheral white blood cells is associated with insulin resistance in adolescents. *Molecular Genetics and Metabolism*, **2010**, 100, 83-7	3.7	52
43	Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. *Atherosclerosis*, **2010**, 209, 585-91	3.1	90
42	Increased levels of resistin in rotating shift workers: a potential mediator of cardiovascular risk associated with circadian misalignment. *Atherosclerosis*, **2010**, 210, 625-9	3.1	37
41	The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. *Pharmacogenetics and Genomics*, **2010**, 20, 1-8	1.9	67
40	Role of genetic variation in insulin-like growth factor 1 receptor on insulin resistance and arterial hypertension. *Journal of Hypertension*, **2010**, 28, 1194-202	1.9	13
39	The impact of maternal high-fat feeding on liver and abdominal fat accumulation in adult offspring under a long-term high-fat diet. *Hepatology*, **2010**, 51, 2234-5	11.2	4
38	Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor □coactivator 1□promoter. *Hepatology*, **2010**, 52, 1992-2000	11.2	233
37	Gene prioritization based on biological plausibility over genome wide association studies renders new loci associated with type 2 diabetes. *Genetics in Medicine*, **2009**, 11, 338-43	8.1	15
36	Maternal pregestational BMI is associated with methylation of the PPARGC1A promoter in newborns. *Obesity*, **2009**, 17, 1032-9	8	124
35	Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease. *Journal of Nutritional Biochemistry*, **2009**, 20, 765-70	6.3	47
34	A diagnostic model to differentiate simple steatosis from nonalcoholic steatohepatitis based on the likelihood ratio form of Bayes theorem. *Clinical Biochemistry*, **2009**, 42, 624-9	3.5	18
33	A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. *Journal of Lipid Research*, **2009**, 50, 2111-6	6.3	276
32	Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. *Atherosclerosis*, **2009**, 206, 119-26	3.1	49
31	Contribution of the functional 5-HTTLPR variant of the SLC6A4 gene to obesity risk in male adults. *Obesity*, **2008**, 16, 488-91	8	49

30	A decreased mitochondrial DNA content is related to insulin resistance in adolescents. *Obesity*, **2008**, 16, 1591-5	8	60
29	Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. *Journal of Hepatology*, **2008**, 48, 125-32	13.4	74
28	Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. *Journal of Hepatology*, **2008**, 49, 600-7	13.4	315
27	Genetic variants in STAT3 are associated with nonalcoholic fatty liver disease. *Cytokine*, **2008**, 44, 201-6	4	44
26	Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with adult treatment panel III criteria in nonobese nondiabetic subjects: response to Musso et al. *Diabetes Care*, **2008**, 31, e42; author reply e43	14.6	9
25	Genetic variants of Clock transcription factor are associated with individual susceptibility to obesity. *American Journal of Clinical Nutrition*, **2008**, 87, 1606-15	7	184
24	Serotonin and serotonin transporter gene variant in rotating shift workers. *Sleep*, **2007**, 30, 1049-53	1.1	18
23	Short allele of serotonin transporter gene promoter is a risk factor for obesity in adolescents. *Obesity*, **2007**, 15, 271-6	8	62
22	Effects of rotating shift work on biomarkers of metabolic syndrome and inflammation. *Journal of Internal Medicine*, **2007**, 261, 285-92	10.8	205
21	Genetics of the cardiometabolic syndrome: new insights and therapeutic implications. *Therapeutic Advances in Cardiovascular Disease*, **2007**, 1, 37-47	3.4	12
20	Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease. *World Journal of Gastroenterology*, **2007**, 13, 4242-8	5.6	88
19	Mitochondrial DNA depletion in small- and large-for-gestational-age newborns. *Obesity*, **2006**, 14, 2193-8	8	68
18	Effect of pregnancy on pre-existing liver disease: chronic viral hepatitis. *Annals of Hepatology*, **2006**, 5, 190-7	3.1	4
17	Liver disease during pregnancy: acute viral hepatitis. *Annals of Hepatology*, **2006**, 5, 231-6	3.1	17
16	Vitamin A toxicity in a physical culturist patient: a case report and review of the literature. *Annals of Hepatology*, **2006**, 5, 293-395	3.1	1
15	The G-308A promoter variant of the tumor necrosis factor-alpha gene is associated with hypertension in adolescents harboring the metabolic syndrome. *American Journal of Hypertension*, **2005**, 18, 1271-5	2.3	28
14	Meta-analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome. *Obesity*, **2005**, 13, 2122-31		111
13	Peroxisome proliferator-activated receptor gamma and its coactivator-1 alpha may be associated with features of the metabolic syndrome in adolescents. *Journal of Molecular Endocrinology*, **2005**, 35, 373-80	4.5	32

12	Intra-host evolutionary dynamics of hepatitis C virus E2 in treated patients. *Journal of General Virology*, **2005**, 86, 2781-2786	4.9	15
11	A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension. *American Journal of Gastroenterology*, **2005**, 100, 636-42	0.7	50
10	Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study. *World Journal of Gastroenterology*, **2005**, 11, 7560-3	5.6	57
9	Evolutionary study of HVR1 of E2 in chronic hepatitis C virus infection. *Journal of General Virology*, **2004**, 85, 39-46	4.9	16
8	A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients. *Annals of Hepatology*, **2003**, 2, 36-40	3.1	2
7	New therapies on the horizon for hepatitis C. *Annals of Hepatology*, **2003**, 2, 164-70	3.1	2
6	Genetic characterization of hepatitis A virus isolates from Buenos Aires, Argentina. *Journal of Medical Virology*, **2002**, 68, 168-74	19.7	26
5	Evaluation of a third generation anti-HCV assay in predicting viremia in patients with positive HCV antibodies. *Annals of Hepatology*, **2002**, 1, 179-82	3.1	4
4	Development of cutaneous sarcoidosis in a patient with chronic hepatitis C treated with interferon alpha 2b. *Journal of Cutaneous Medicine and Surgery*, **2001**, 5, 406-8	1.6	22
3	Relationship between diversity of hepatitis C quasispecies and histological severity of liver disease. *Medicina*, **2000**, 60, 587-90	1	1
2	High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus. *Archives of Dermatology*, **1999**, 135, 1000-1		57
1	Hepatitis C virus antibody (anti-HCV): prevalence in psoriasis. *International Journal of Dermatology*, **1996**, 35, 797-9	1.7	35